Abstract 1216: assays for the selection and functional characterization of antibody-drug conjugates at the National Research Council of Canada

From National Research Council Canada

DOIResolve DOI: https://doi.org/10.1158/1538-7445.AM2016-1216
AuthorSearch for: 1; Search for: 1; Search for: 1; Search for: 1; Search for: 1; Search for: 1
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
FormatText
TypeArticle
Proceedings titleProceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA
Series titleCancer Research; Volume 76
ConferenceAACR 107th Annual Meeting 2016, April 16-20, 2016, New Orleans, LA
ISSN0008-5472
1538-7445
Abstract
One of the most promising and fastest growing classes of cancer therapeutics builds on the molecular targeting abilities of antibodies by combining them with drugs to generate highly specific antibody-drug conjugates (ADCs). However, the development of ADCs requires time-consuming selection of the antibody for every target and cancer type. Screening technologies based on the use of conjugated secondary antibodies provide a fast and efficient surrogate assay from which to identify which antibodies are best internalized and suitable for immunoconjugate development into ADCs.
Publication date
PublisherAmerican Association for Cancer Research
LanguageEnglish
Peer reviewedYes
NPARC number23000714
Export citationExport as RIS
Report a correctionReport a correction
Record identifier567ed20b-bd54-4fdf-a87b-b69bdd6ef870
Record created2016-08-31
Record modified2020-03-16
Report a problem on this page
Date modified: